Holen Sie sich die Stockscreener-App
1.06
1.92%
0.02
Schlusskurs vom Vortag:
$1.04
Offen:
$1.03
24-Stunden-Volumen:
39,153
Relative Volume:
0.44
Marktkapitalisierung:
$5.95M
Einnahmen:
$125.00K
Nettoeinkommen (Verlust:
$-14.64M
KGV:
-0.2051
EPS:
-5.1674
Netto-Cashflow:
$-15.06M
1W Leistung:
-0.93%
1M Leistung:
-24.29%
6M Leistung:
-66.35%
1J Leistung:
-77.92%
1-Tages-Spanne:
$1.03
$1.07
1-Wochen-Bereich:
$0.96
$1.12
52-Wochen-Spanne:
$0.96
$5.29
Imunon Inc Stock (IMNN) Company Profile
Firmenname
Imunon Inc
Sektor
Branche
Telefon
(609) 896-9100
Adresse
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.06 | 5.95M | 125.00K | -14.64M | -15.06M | -5.1674 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Imunon Inc Aktie (IMNN) Neueste Nachrichten
IMUNON Converts $1.2 Million of Debt-to-Equity - GlobeNewswire
A debt swap cuts IMUNON’s outstanding debt by about 43%, with no common shares issued. - Stock Titan
A 7,169-share salary award leaves Imunon (IMNN) chair with 103,921 shares held directly. - Stock Titan
Part of the CEO’s salary came as stock: Imunon (IMNN) granted Stacy Lindborg 6,697 shares. - Stock Titan
At $1.41 a share, Imunon (IMNN) granted its medical chief 4,390 shares in place of part of his cash salary. - Stock Titan
Imunon Inc (NASDAQ: IMNN) Share Price, IMNN Stock News, IMNN Share Price & Updates - kalkine.com.au
Imunon (IMNN) chair takes stock instead of cash pay - Stock Titan
Imunon (IMNN) CEO adds 5,504 shares in stock grant - Stock Titan
Imunon (IMNN) pays its chief medical officer in stock - Stock Titan
IMUNON partners with National Cancer Institute to expand IL-12 DNA plasmid beyond ovarian cancer - AllSci
Imunon (IMNN) Partners with NCI on IMNN-001 Immunotherapy Amid V - GuruFocus
IMUNON Enters CRADA with NCI’s CTEP to Advance IMNN-001 in New Cancer Indications and Combinations - Quiver Quantitative
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 - Yahoo Finance
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy By Investing.com - Investing.com Australia
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Australia
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Canada
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com UK
IMUNON Announces Full Agenda and Speaker Lineup Ahead of - GlobeNewswire
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Nigeria
Imunon (IMNN) Slips 2.5% to $1.54, Approaching Critical Support at $1.46Stock Analysis - siam.in
Imunon (IMNN) Slips 2.5% to $1.56 as Range-Bound Trading Keeps Key Levels in FocusCharm Flow - siam.in
Imunon Inc (IMNN) Insider Sell: General Counsel and Corp Sec Susan Eylward Sells 2,525 Shares - GuruFocus
Insider at Imunon (NASDAQ: IMNN) logs new stock trade - Stock Titan
Imunon (IMNN) insider reports new stock trade - Stock Titan
Imunon (IMNN) counsel takes salary in stock, then sells the same number of shares days later - Stock Titan
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com Canada
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com India
Imunon to host R&D day on Sept. 23 for ovarian cancer therapy - Investing.com India
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com UK
Imunon to host R&D day on Sept. 23 for ovarian cancer therapy - Investing.com UK
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com
Imunon (IMNN) Financial Update: EPS Prints Above Forecast on the Day; The Stock Ends Down 3.05% in the Current UpdateGross Profit Margin - dars.gov.et
Imunon (IMNN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: The Stock Records a 3.80% Increase in the Current UpdateQuarterly Profit Report - vinanet.vn
Imunon (IMNN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: The Stock Records a 3.80% Increase in the Current UpdateGuidance vs Actual - dars.gov.et
Imunon Earnings Call Highlights Survival Gains, Cash Needs - TipRanks
Imunon (IMNN) Q2 2026 Filing Snapshot: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Stock Move: Shares Move 1.25% Lower on the DayEarnings Revision Upgrade - vinanet.vn
Imunon (IMNN) General Counsel and Corp Sec Susan Eylward Sells 2,449 Shares - GuruFocus
Imunon (IMNN) CEO takes 6,615 shares instead of cash pay - Stock Titan
Imunon (IMNN) pays CMO with 3,516-share stock grant - Stock Titan
Imunon (IMNN) pays executive chair with 7,147 shares - Stock Titan
Imunon (IMNN) counsel gets stock in lieu of pay, then sells 2,449 shares - Stock Titan
Imunon (IMNN) Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.43% BounceProduct Revenue Analysis - vinanet.vn
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Fair Value Gap - dars.gov.et
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Gamma Exposure - vinanet.vn
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Sector Neutral Pair - careplusvn.com
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Triple MA Cross - dars.gov.et
Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund - Stock Titan
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - kalkine.ca
Earnings call transcript: Imunon beats Q2 2026 EPS forecast as shares stay weak - Investing.com UK
Maxim Group Maintains Imunon(IMNN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Finanzdaten der Imunon Inc-Aktie (IMNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Imunon Inc-Aktie (IMNN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Eylward Susan | General Counsel and Corp Sec |
Aug 17 '26 |
Sale |
1.63 |
2,449 |
3,993 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Aug 03 '26 |
Sale |
1.57 |
2,541 |
3,977 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jul 20 '26 |
Sale |
1.78 |
2,150 |
3,830 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jul 06 '26 |
Sale |
1.88 |
920 |
1,730 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jun 29 '26 |
Sale |
1.75 |
11,800 |
20,674 |
2,896 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):